Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AstraZeneca 4Q Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

AstraZeneca 4Q Results

Revenues up 18% in the quarter driven by oncology and respiratory sales.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Image: AstraZeneca

AstraZeneca
4Q Revenues: $14.9 billion (+24%)
4Q Earnings: $1.5 billion (+56%)
FY Revenues: $54.1 billion (+18%)
FY Earnings: $7.0 billion (+18%)
Comments: Oncology sales were $22.4 billion, up 21%. Tagrisso sales were $1.7 billion in the quarter, up 20%. Imfinzi sales were $1.3 billion, up 16%. Lynparza sales were up 46% to $1.4 billion.

Cardiovascular, Renal and Metabolism (CVRM) sales were up 16% in the quarter. Farxiga sales were up 21% to $1.9 billion. Brilinta sales were $341 million, up 4%. Crestor sales were up 5% to $261 million.

Respiratory & Immunology (R&I) sales in the quarter were up 27% to $2.1 billion. Symbicort sales were $684 million, up 31%. Fasenra sales were up 12% to $471 million. Breztri sales were up 29% to $257 million. This growth offset declines for Pulmicort, down 25% to $164 million.

Vaccines and Immune Therapies (V&I) sales were $651 million, up 58% driven by Beyfortus with $403 million in sales, offsetting losses for Synagis, down 38% to $101 million, and COVID mAbs.

Rare disease revenue was up 21% to $2.4 billion. Ultomiris sales were up 32% to $1.1 billion. Soliris sales were down 24% to $543 million. Strensiq sales were $420 million, up 38%.

Total Revenue by medicine includes Alliance Revenue and Collaboration Revenue within each revenue figure.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics